Introduction
After allogeneic stem cell transplantation (allo-SCT), donor T cells play an important role in graft-versus-host disease (GVHD), in facilitating haematopoietic donor engraftment and in the graft-versus-leukaemia effect (GVL). Thus, T-cell depletion of the graft decreases the risk of GVHD, but it is also associated with higher rates of graft rejection and leukaemia relapse. 1 The higher incidence of these two complications probably reflects the poor capability of a T-cell depleted (TCD) graft to eradicate host lympho-myelopoiesis. In fact, recipients of a TCD graft have a higher incidence of mixed chimerism (MC). [2] [3] [4] [5] [6] [7] [8] The predictive value of MC in an individual patient for either graft rejection or relapse is controversial. [9] [10] [11] [12] Some studies indicate that MC is associated with these complications, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] while others do not corroborate this finding. 24, 25 The lack of association of MC with graft rejection and relapse in some studies might be because of the fact that chimerism was not analysed in the cell subsets responsible for these complications. Since graft rejection is caused by host T cells surviving the conditioning regimen, 26 serial measurement of host T cells might predict this complication. Likewise, serial measurement of host myeloid cells in patients diagnosed with a myeloid malignancy might predict leukaemia relapse. Moreover, whereas several studies have analysed the chimerism status of patients submitted to allogeneic TCD bone marrow transplants, very few studies have addressed the chimerism status of T cells and neutrophils after allogeneic TCD peripheral blood transplantation. 27, 28 In this prospective single-centre study, we investigated the predictive value of MC, analysing it in pure populations of T cells and neutrophils in 22 patients treated with an allogeneic peripheral blood transplant, TCD by CD34 + selection (allo-PBT/CD34 + ). These results were compared with a concurrent cohort of 18 patients submitted to an unmodified allogeneic transplant (allo-SCT; 13 allogeneic bone marrow transplants and five allo-PBT). Our findings show that this approach improves the predictive value of detecting MC for graft rejection and leukaemia relapse in allo-PBT/CD34 + patients. /kg), respectively (P ¼ 0.0008). The median (range) follow-up was 11 months . Granulocyte colony-stimulating factor (G-CSF) administration to the donors, peripheral blood stem cells (PBSCs) harvest, and CD34 + positive selection method were performed as previously reported. 29, 30 Samples Peripheral blood samples (10 ml) were collected before transplantation to identify PCR-STR informative fragments for each Quantification of lymphoid and myeloid chimerism using multiplex PCR amplification F Fernández-Avilés et al donor-recipient pair. After transplantation, chimerism status was assessed on peripheral blood samples collected at day +28, and monthly for 6 months, which was continued every month in those patients with MC, and every 3 months for patients with complete donor chimerism (CC). Chimerism status was monitored in T lymphocytes and neutrophils, which were separated by an immunomagnetic method (MiniMacs; Miltenyi) using a Pan T-cell isolation Kit (Miltenyi) and a density-gradient (the cell bottom was obtained after Dextran-Ficoll separation), respectively. In the T-cell fraction, more than 95% of cells were CD3 + , assessed by flow cytometry. We considered MC to be present when more than 5% of host cells was detected.
Materials and methods

Patients
DNA extraction
High-molecular-weight DNA was extracted from mononuclear cells isolated by Ficoll-Isopaque density-gradient centrifugation. 31 For samples containing less than 5 Â 10 6 cells, DNA was extracted using silica membranes (Qiamp Blood Kit, Qiagen), as recommended by the manufacturer. After transplantation, DNA was extracted from peripheral blood T cells and neutrophils. 32, 33 DNA was quantified using standard UV-absorption at 260 nm and all samples were diluted to a final concentration of 0.2 ng/ml in H 2 O.
STR amplification
PCR was performed using the AmpFlSTR Profiler Plus PCR amplification Kit (Perkin-Elmer) as recommended by the manufacturer. Briefly, 2 ng of DNA were subjected to 2400 PCR thermocycler (Perkin-Elmer) in a final volume of 25 ml. The STR loci amplified were: D3S1358, vWA, FGA (all labelled with 5-FAM); D8S1179, D21S11, and D18S51 (all labelled with JOE); D5S818, D13S317, and D7S829 (all labelled with NED), and the amelogenin locus (labeled with JOE), which discriminates between X and Y chromosomes. The cycle conditions were: 951C for 11 min, followed by 28 cycles at 941C for 1 min, 591C for 1 min, and 721C for 1 min, with a final elongation step of 45 min at 601C. Separation and detection of the amplified PCR products were performed on an ABI PRISM 310 automated DNA sequencer (Applied Biosystems). Fragment sizes were automatically determined using ABI PRISM GeneScan 2.0 and GenoTyper software (Applied Biosystems). Quantification of MC was performed by determining the ratio of peak areas from donor and recipient informative alleles, as described ( Figure 1) . 33 Using this method, the most consistent level of sensitivity was of 5% (Figure 2 ).
Statistical analysis
Differences in continuous variables were analysed with Student's t-test or the Mann-Whitney U-test for variables not following a normal distribution. Fisher's exact test (two tailed) was used to test associations between categorical variables.
Results
Informative microsatellites and period of study
All donor-recipient pairs displayed at least one informative microsatellite, with a median (range) of five (1) (2) (3) (4) (5) (6) (7) (8) (9) . Chimerism studies were performed between 28 days and 25 months after transplantation, with a median (range) study period of 9 (3-25) months for allo-PBT/CD34 + , and of 13 (3-24) months for allo-SCT (P ¼ NS). At the beginning of the study, we analysed samples from both whole blood and separated cell subpopulations. However, we soon decided to perform chimerism studies only on fractionated cells, since this approach seemed to be more sensitive and more informative. Thus, in four whole-blood samples showing CC, MC, at a level ranging between 8 and 11% of host cells, was detected when analysed in separated T cells. Moreover, when two whole-blood samples showing a low degree of mixed chimerism (7 and 12% of host cells, respectively) were analysed in cell subpopulations, MC in T cells (16 and 40% of host cells, respectively) but not in myeloid cells was detected. The results of chimerism studies in both groups of patients are detailed in Figures 3 and 4 , respectively.
Complete donor chimerism (CC; n ¼ 20)
CC at all time points was documented in 20 (50%) patients. The incidence of CC was significantly lower in the allo-PBT/CD34 + group as compared to the allo-SCT group: 23 vs 83%, Abbreviations: Allo-PBT/CD34 + = T-cell depleted peripheral blood graft by means of CD34 + selection; Allo-SCT = unmodified allogeneic stem cell transplantation; allo-BMT = allogeneic bone marrow transplantation; allo-PBT: allogeneic peripheral blood transplantation. D = donor; R = recipient. M = male; F = female. CR = complete remission; PR = partial remission. CML = chronic myeloid leukaemia; AML = acute myeloid leukaemia; B-ALL = acute lymphoblastic leukaemia of B-lineage; RAEB = refractory anaemia with excess blast; Biph AL = biphenotypic acute leukaemia; CLL = chronic lymphocytic leukaemia; AAS = aplastic anaemia. CY = cyclophosphamide; TBI = total-body irradiation; BU = busulphan; TAI = thoracic-abdominal irradiation. * Â 10 À6 per kg body weight. CsA = cyclosporine A; MTX = methotrexate; aGVHD = acute graft-versus-host disease; cGVHD = chronic graft-versus-host disease.
Quantification of lymphoid and myeloid chimerism using multiplex PCR amplification F Fernández-Avilés et al respectively (P ¼ 0.0003). None of the patients with CC developed graft rejection, but two of them relapsed, both diagnosed with acute lymphoblastic leukaemia-Ph+ of B-lineage (Table 1 ; Figure 4 ). Quantification of lymphoid and myeloid chimerism using multiplex PCR amplification F Fernández-Avilés et al allo-SCT (P ¼ 0.0003). This difference was because of a much higher frequency of TcMC in the allo-PBT/CD34 + group as compared to the allo-SCT group: 16 of 22 (72.3%) vs one of 18 (5.5%), respectively (P ¼ 0.0001). In contrast, the incidence of MyMC was similar in both groups: four of 22 (16%) vs three of 18 (17%), respectively (P ¼ NS). Of the 20 patients with MC, 13 displayed pure TcMC, three pure MyMC, and four both TcMC and MyMC.
Clinical relevance of T-cell MC (TcMC; n ¼ 17)
Six patients showed a transient presence of host T cells during their evolution, the proportion of host lymphoid cells being o20%. After a median (range) follow-up of 15 (7-25) months, graft rejection was not observed. A further seven patients displayed a persistent proportion of host T cells, six of which ranged between 10 and 30%, whereas one patient displayed a Table 1 .)
Quantification of lymphoid and myeloid chimerism using multiplex PCR amplification F Fernández-Avilés et al quantity of host T cells of 50% (Figure 3) . After a median (range) follow-up of 9 (3-13) months, none of them have developed graft rejection. In four patients TcMC was associated with pancytopenia, in all of them the proportion of host lymphoid cells being 430% at the time of a drop in peripheral blood counts. Three of the four patients were treated with globulin antithymocyte and infusion of G-CSF mobilised PBSCs, but died because of either graft rejection or GVHD (Table 1) ; the fourth patient responded to immunosuppresive therapy with cyclosporine A and was alive and well at the last follow-up, although CC was not restored (Figure 3) . None of the 17 patients displaying TcMC developed acute GVHD grade II-IV, as compared to five of the 23 patients with 100% of donor T cells (P ¼ 0.06; Fisher exact P, two-tailed).
Clinical relevance of myeloid MC (MyMC; n ¼ 7)
Five out of seven (71%) patients with MyMC relapsed as compared to only one out of 13 (8%) patients exhibiting a pure TcMC (P ¼ 0.007), and to two of the 20 (10%) patients with CC (Po0.0001). The five relapsing patients with MyMC had been diagnosed with chronic myeloid leukaemia (CML), and exhibited a pattern of increasing (Z30%) recipient myeloid cells (Figures 3 and 4) . In all cases Ph+ metaphases were apparent in bone marrow (ranging between 15 and 50%) and BCR/ABL transcripts were detected by PCR when host myeloid cells were observed in peripheral blood by PCR/STR. After stopping cyclosporine A or administering DLI, all these cases became BCR/ABL negative and MC reverted to CC. Three patients relapsed while showing 100% of donor myeloid cells; all of them were diagnosed with acute lymphoblastic leukaemia of Blineage.
Discussion
Follow-up of haematopoietic donor chimerism after allogeneic transplantation is a useful tool for confirming the stability of lymphoid and myeloid donor engraftment. 34, 35 This is of particular importance for patients at high risk of graft rejection or leukaemia relapse, which is the case of those receiving a TCD graft [1] [2] [3] [4] [5] [6] [7] [8] or a nonmyeloablative SCT. 36 Detection of increasing quantities of lymphoid and myeloid host cells might be predictive of graft rejection and leukaemia relapse, respectively. This might provide important information as to when early therapeutic interventions, such as donor lymphocyte infusions (DLI), should be made. 36, 37 A sensitive and automatic method of quantifying the degree of MC after allo-SCT, based on PCR assays of polymorphic short tandem repeats (STR), is available. 33 Graft rejection seems to be caused by host T cells surviving the conditioning regimen. Thus, a direct association of the number of residual T cells with the incidence of graft rejection has been shown. 38 Graft rejection is one of the most severe complications after allogeneic transplants, with a mortality rate of 50%.
1 Leukaemia relapse may be predicted, at least for patients diagnosed with myeloid malignancies, by detecting increasing quantities of host-myeloid cells. 39 With this background, we hypothesised that the predictive value of chimerism studies might be improved by using a quantitative PCR/STR technique in separated T cells and neutrophils. We applied this method to patients submitted to an allo-PBT/CD34 + , since this type of transplant is associated with a lower incidence of GVHD, but at the cost of a higher incidence of graft rejection and leukaemia relapse. 1 Moreover, whereas many data on chimerism after allogeneic bone marrow transplant are available, very few studies have addressed the chimerism status of T cells and neutrophils after allogeneic peripheral blood transplantation. 27, 28 We observed that the incidence of MC was significantly higher in the allo-PBT/CD34 + group as compared to the unmodified allo-SCT group: 77 vs. 17%, respectively (P ¼ 0.0003). This difference was because of a much higher frequency of TcMC in the first group (72.3 vs 5.5%; P ¼ 0.0001). This result is striking given that these patients, compared to recipients of a T-cell-replete allo-SCT, had received a more intensive conditioning regimen (13 Gy of TBI compared to 12 Gy) and a higher quantity of CD34 + cells (median of 4.8 Â 10 6 /kg vs. 2.9 Â 10 6 /kg; P ¼ 0.04). This result highlights the key role of donor T cells in the elimination of residual host T cells.
1 Surprisingly, the appearance of TcMC had no clinical consequences in most of the patients. Thus, in 13 out of 17 (76.5%) patients with TcMC, the presence of recipient T cells was transient, or stable for several months, and only in four cases (23.5%) progressed to graft rejection or pancytopenia. Of note, in these four patients the proportion of recipient lymphoid cells was 430%, a level which was reached in only one patient with a stable TcMC. A long-lasting stable T-cell MC after TCD allo-SCT has been observed by other groups. 5, [40] [41] [42] The association between TcMC and relapse is controversial. Whereas some authors find a higher incidence of relapse in patients with TcMC, 4, 8, 24 in this and in other studies 40, 43 no statistical difference in relapse incidence was found between TcMC and CC groups. In this sense, very recent results suggest in order for donor lymphocytes to eradicate leukaemic cells, a certain degree of residual host lymphohaematopoietic chimerism might be required. 44, 45 As in other studies, we found a trend for a lower incidence of acute GVHD grade II-IV for patients with TcMC, 13, 16, 46 supporting the concept that host T cells may also induce tolerance in donor haematopoietic cells. 47 A few patients (17.5%) disclosed a pattern of MyMC, which was observed in a similar proportion in both groups of patients. In contrast to the herein-observed stable equilibrium of host and donor T cells in most of the patients with TcMC, the presence of host myeloid cells was followed by a leukaemia relapse in most (71%) of the instances. Relapsing patients exhibiting MyMC were diagnosed with CML, and in all cases Ph+ metaphases were apparent in bone marrow (ranging between 15 and 50%) when host myeloid cells were detected in peripheral blood by PCR/STR. The growing proportion of host myeloid cells in these cases supported the decision to either stop cyclosporine A or administer DLI. After these therapeutic interventions, all these cases became BCR/ABL negative and MC reverted to CC. In this series, two of the patients who relapsed exhibited complete Tlymphoid and myeloid donor chimerism. Of note, these two patients were diagnosed with acute lymphoblastic leukaemia of B-lineage. Similarly, recent reports showed that in patients suffering late relapses from acute leukaemia or myelodysplastic syndrome, the only cells of host origin present were leukaemic cells. 15, 43 In conclusion, chimerism analysis in T cells and neutrophils from peripheral blood by means of PCR/STR allows a better understanding of allogeneic reactions in individual patients, and is useful for predicting graft rejection and myeloid relapse in allo-PBT/CD34 + patients. These results might also be taken into consideration in allo-SCT with immunosuppressive conditioning regimens, rather than in myeloablative ones, which aim to facilitate the eradication of host haematopoietic and malignant cells by allogeneic cells. In these nonmyeloblative allo-SCT, precise information on the degree of T-lymphoid and myeloid donor chimerism is crucial when deciding therapeutic interventions, such as DLI. 48 Characterisation of the donor vs host origin of other cell lineages in patients undergoing allo-SCT is of increasing interest. It is likely that direct presentation of recipient alloantigens to residual host dendritic cells plays a major role in the activation of donor T cells, resulting in GVHD. 49 Moreover, the total number of donor type 2 dendritic cell progenitors administered to patients has been associated with decreased chronic GVHD and GVL effects in allo-SCT. 50 The different role of donor and host dendritic cells in GVHD and GVL reactivity has prompted us to investigate the chimerism status of type 1 and 2 dendritic cells after allo-SCT.
